Related Experiment Video
Updated: Sep 23, 2025
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
Gene expression signatures in early breast cancer: Better together with clinicopathological features
Leandro Jonata Carvalho Oliveira1, Larissa Costa Amorim1, Thais Baccili Cury Megid2
1Grupo Oncoclínicas (GOC), Centro Paulista de Oncologia (CPO) - Unidade Faria Lima, Av. Brigadeiro Faria Lima, 4300, São Paulo, SP 04538-132, Brazil.
Abstract:
Breast cancer (BC) is a highly heterogeneous disease, characterized by a variety of subtypes with distinct biological, molecular, and clinical behavior. Standard clinicopathological and tumor biology information (as assessed by gene expression signatures-GES), have provided enhanced prognostic and predictive information in both node-negative(N0) and positive(N +), hormonal receptor positive/human epidermal growth factor 2 negative (HR+/HER2-) early breast cancer (EBC). Herein, we comprehensively review the clinical data of 5 commonly used GES, namely, Oncotype DX(ODX)®; MammaPrint (MP)®; Prosigna®; Breast Cancer Index (BCI)® and Endopredict® - with sections specifically addressing the role of GES in special histologic subtypes, premenopausal women, late recurrence and adjuvant treatment de-escalation.
